You have to wonder why, page-23

Moosey

Are you referring to the licensing agreement update announcement of 10 September?

As Mylan had publicly indicated that it was now selling a generic daptomycin product, POH stated that it considered that such sales would be restrained under the terms of the 2012 licensing agreement between Agila Strides and Phosphagenics. POH then said that it was reserving its rights in the matter.

If POH wishes to take action, I would think it would need to follow the dispute procedure nominated in the 2012 licensing agreement. I would question the Board or shareholders' enthusiasm for further action.